STAT
OCTOBER 25, 2023
Oncologists were more likely to provide low-value cancer care after receiving money from pharmaceutical companies, and the findings raise questions about the extent to which industry influence may have led to patient harm, according to a new study. Continue to STAT+ to read the full story…
STAT
JANUARY 10, 2024
This latest revision, known as the DSM-5-TR, was prepared between 2016 and 2019, and published in 2022. The researchers found that, of the 55 physicians with ties to a pharmaceutical company, 91% accepted food and beverages, and 69% received compensation for travel and consulting, according to the analysis published in the BMJ.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JUNE 25, 2024
Pharmaceutical companies in the U.K. Between 2004 to 2021, the Prescription Medicines Code of Practice Authority, a self-regulatory body overseen by the Association of the British Pharmaceutical Industry, ruled on more than 1,100 cases involving nearly 160 companies where there was a breach of the industry code.
STAT
JULY 17, 2024
Senate had achieved a breakthrough in the battle to prevent pharmaceutical companies from abusing the patent system, an issue that has been blamed for boosting prescription drug costs for Americans. John Cornyn (R-Texas), boasted that the bill, which was first introduced in May 2019 , would thwart the use of so-called patent thickets.
STAT
DECEMBER 7, 2023
In 1997, Celgene obtained a key patent for what would become a blockbuster blood cancer treatment, giving it a monopoly until 2019. But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work.
Drug Patent Watch
DECEMBER 10, 2024
The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48 As a result, many companies are turning to integrated CDMOs to simplify their outsourcing processes and improve efficiency. 2019, March 14). from 2023 to 2030. Retrieved from [link] Pfizer CentreOne.
Express Pharma
JUNE 11, 2024
With the evolving landscape of drug development and innovations, several institutes are serving as catalysts by partnering with pharmaceutical companies to drive progress at various stages of research and development. All Phases of clinical trials witnessed a substantial CAGR of 30 per cent from 501 in 2019 to 1,893 in 2023 in China.
Expert insights. Personalized for you.
362 
Let's personalize your content